Jaguar Health Announces Study Results Showing Twice Daily Crofelemer Administration Reduces Abdominal Pain And Improves Stool Consistency In Functional Diarrhea Patients Compared To Placebo
Portfolio Pulse from Benzinga Newsdesk
Jaguar Health announced that a study showed twice-daily administration of Crofelemer significantly reduces abdominal pain and improves stool consistency in patients with functional diarrhea compared to a placebo.
May 28, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jaguar Health's study results indicate that Crofelemer, when administered twice daily, significantly reduces abdominal pain and improves stool consistency in functional diarrhea patients compared to a placebo.
The positive study results for Crofelemer could lead to increased investor confidence and potential market demand for the drug, positively impacting Jaguar Health's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100